MEP32308A - Pharmaceutical composition containing histone deacetylase inhibitor - Google Patents

Pharmaceutical composition containing histone deacetylase inhibitor

Info

Publication number
MEP32308A
MEP32308A MEP-323/08A MEP32308A MEP32308A ME P32308 A MEP32308 A ME P32308A ME P32308 A MEP32308 A ME P32308A ME P32308 A MEP32308 A ME P32308A
Authority
ME
Montenegro
Prior art keywords
histone deacetylase
deacetylase inhibitor
pharmaceutical composition
composition containing
containing histone
Prior art date
Application number
MEP-323/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Osamu Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MEP32308A publication Critical patent/MEP32308A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
MEP-323/08A 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor MEP32308A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26
YUP-2005/0884A RS20050884A (xx) 2003-05-26 2004-05-26 Farmaceutski preparat koji sadrži inhibitor histonske deacetilaze
PCT/JP2004/007562 WO2004103369A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Publications (1)

Publication Number Publication Date
MEP32308A true MEP32308A (en) 2010-10-10

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-323/08A MEP32308A (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Country Status (27)

Country Link
US (1) US20070098816A1 (xx)
EP (1) EP1626719A1 (xx)
JP (1) JP2006526031A (xx)
KR (1) KR100938712B1 (xx)
CN (2) CN101322707A (xx)
AR (1) AR045318A1 (xx)
AU (1) AU2004241873C1 (xx)
BR (1) BRPI0410959A (xx)
CA (4) CA2634765A1 (xx)
CL (1) CL2004001278A1 (xx)
CO (1) CO5660262A2 (xx)
CR (1) CR8163A (xx)
CU (1) CU23490B7 (xx)
EC (1) ECSP056253A (xx)
IL (1) IL171941A0 (xx)
ME (1) MEP32308A (xx)
MX (1) MXPA05012345A (xx)
NO (1) NO20055417L (xx)
NZ (1) NZ543591A (xx)
PE (1) PE20050206A1 (xx)
RS (1) RS20050884A (xx)
RU (1) RU2322971C2 (xx)
TW (1) TW200505424A (xx)
UA (1) UA81499C2 (xx)
UY (1) UY28330A1 (xx)
WO (1) WO2004103369A1 (xx)
ZA (1) ZA200509515B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
MXPA06003222A (es) * 2003-09-25 2006-05-22 Astellas Pharma Inc Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
WO2006099396A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
AU2006226861B2 (en) 2005-03-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
CA2642273C (en) 2006-02-14 2016-09-20 President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
ES2481413T3 (es) 2006-02-14 2014-07-30 The President And Fellows Of Harvard College Inhibidores de histona desacetilasa
JP5497431B2 (ja) 2006-05-03 2014-05-21 プレジデント アンド フェローズ オブ ハーバード カレッジ ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
DK2099442T3 (en) 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009079375A1 (en) * 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
JP5665740B2 (ja) 2008-07-23 2015-02-04 プレジデント アンド フェローズ オブ ハーバード カレッジ デアセチラーゼ阻害剤およびその使用
PE20110677A1 (es) * 2008-08-29 2011-09-16 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
PT3354650T (pt) 2008-12-19 2022-06-20 Vertex Pharma Compostos úteis como inibidores da cinase atr
US20120034302A1 (en) * 2009-02-11 2012-02-09 Liangping Yu Particulate composition and the method of making the same
NZ596365A (en) * 2009-05-01 2013-11-29 Oncozyme Pharma Inc Pentamidine combinations for treating cancer
JP5586692B2 (ja) * 2009-06-08 2014-09-10 ギリアード サイエンシーズ， インコーポレイテッド アルカノイルアミノベンズアミドアニリンｈｄａｃインヒビター化合物
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
EP2470173B1 (en) * 2009-08-25 2016-04-27 Abraxis BioScience, LLC Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
CA2850566C (en) 2011-09-30 2022-05-03 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
IN2014CN02501A (xx) 2011-09-30 2015-06-26 Vertex Pharma
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
JP2015515478A (ja) 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物及びそれらの併用療法
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
WO2014141129A2 (en) * 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
WO2015127227A1 (en) * 2014-02-21 2015-08-27 Cleveland Biolabs, Inc. Uses of flagellin for improved chemotherapy
EP3194387B1 (en) 2014-09-17 2019-07-31 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CA3000684A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
PL348673A1 (en) * 1998-09-25 2002-06-03 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
DE60045890D1 (de) * 1999-04-27 2011-06-09 Mitsubishi Tanabe Pharma Corp Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen
CN1387438A (zh) * 1999-11-10 2002-12-25 沃尼尔·朗伯公司 联合化学疗法
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
KR100938712B1 (ko) 2010-01-25
AU2004241873B8 (en) 2008-05-29
CU23490B7 (es) 2010-02-23
CN1794991A (zh) 2006-06-28
CR8163A (es) 2006-07-14
US20070098816A1 (en) 2007-05-03
TW200505424A (en) 2005-02-16
CA2634709A1 (en) 2004-12-02
ECSP056253A (es) 2006-10-25
CL2004001278A1 (es) 2005-05-06
PE20050206A1 (es) 2005-03-26
ZA200509515B (en) 2006-07-26
RU2005140570A (ru) 2006-06-10
NO20055417D0 (no) 2005-11-16
CA2634765A1 (en) 2004-12-02
NO20055417L (no) 2005-12-19
AU2004241873C1 (en) 2009-01-22
KR20060009371A (ko) 2006-01-31
MXPA05012345A (es) 2006-02-08
RS20050884A (xx) 2008-04-04
CA2634766A1 (en) 2004-12-02
CO5660262A2 (es) 2006-07-31
BRPI0410959A (pt) 2006-07-04
AR045318A1 (es) 2005-10-26
CN101322707A (zh) 2008-12-17
UA81499C2 (en) 2008-01-10
RU2322971C2 (ru) 2008-04-27
JP2006526031A (ja) 2006-11-16
IL171941A0 (en) 2006-04-10
EP1626719A1 (en) 2006-02-22
AU2004241873A1 (en) 2004-12-02
UY28330A1 (es) 2004-12-31
AU2004241873B2 (en) 2008-05-08
NZ543591A (en) 2009-09-25
CA2527191A1 (en) 2004-12-02
WO2004103369A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
MEP32308A (en) Pharmaceutical composition containing histone deacetylase inhibitor
NO20055216D0 (no) Nye hydroksamater som terapeutiske midler
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
NO20044135L (no) Piperazinyl-, piperidinyl- og morfolinylderivater som nye inhibitorer av histon-deacetylase
NO20044146L (no) Karbonylaminoderivater som nye inhibitorer av histon-deacetylase
EA200700143A1 (ru) Производные замещенного пропенилпиперазина в качестве новых ингибиторов гистондеацетилазы
NO20044444L (no) Benzamidderivater nyttige som histondeacetylase inhibitorer
CY1109331T1 (el) Παραγωγα αμινοφαινυλιου ως νεοι αναστολεις της αποακετυλασης ιστονης
NO20044194L (no) Nye inhibitorer av histon-deacetylase
ME00566A (en) Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
AR042851A1 (es) Acidos hidroxamicos inhibidores de histona desacetilasa
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
EA200701970A1 (ru) Гидроксаматы как ингибиторы гистондеацетилазы и содержащие их фармацевтические композиции
MX2013004117A (es) Formulacion farmaceutica para inhibidores de histona desacetilasa.
SV2006002109A (es) Una composicion farmaceutica antimicobacteriana
EP4110781A4 (en) 1,3,4OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONEDEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITION THEREOF
EP4110780A4 (en) COMPOUNDS DERIVED FROM 1,3,4-OXADIAZOLE USED AS HISTONE DEACETYLASE 6 INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
MX2008008470A (es) Nuevos derivados pirrolicos con actividad inhibidora de desacetilasa de histonas.
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
EP4136085A4 (en) 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF
EA201170950A1 (ru) Новая комбинация активных ингредиентов, содержащая нестероидное противовоспалительное лекарственное средство и производное колхикозида
EA201992296A1 (ru) Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета
TH81162A (th) สารผสมทางเภสัชกรรมที่มีตัวยับยั้งฮิสโตนดีอะซีทิลเลส
PE20212078A1 (es) Inhibidor de mpges 1 para el tratamiento de dolor de osteoartritis